Difference in the Incidences of the Most Prevalent Urologic Cancers from 2003 to 2009 in Iran

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 15; no. 3; pp. 1459 - 1463
• Main Authors: Basiri, Abbas, Shakhssalim, Nasser, Jalaly, Niloofar Yahyapour, Miri, Hamid Heidarian, Partovipour, Elham, Panahi, Mohammad Hossein
• Format: Journal Article
• Language: Korean
• Published: 2014
• Subjects: epidemiology; gender specificity; Iran; Urologic cancer; change over time
• ISSN: 1513-7368; 2476-762X

Background: Urological cancers represent a major public problem associated with high mortality and morbidity. The pattern of these cancers varies markedly according to era, region and ethnic groups, but increasing incidence trends overall makes focused epidemiological studies important. The aim of the present study was to assess the incidence of most prevalent urological cancers in Iran from 2003 to 2009. Materials and Methods: The data for this study were obtained from the population-based Cancer Registry Center of the Iran Ministry of Health and Medical Education. Differences of mean age and age distributions of each cancer were compared between 2003 and 2009 in men and women. Results: Bladder cancer was the most common urologic cancer in both genders. The rate difference of age standardized ratio (ASR) of bladder and renal cell carcinoma in women were 1.54 and 2.01 percent per 100,000 population from 2003 to the 2009, respectively. In men, the rate difference of age standardized ratio of prostate, testis, kidney and bladder cancer was also 2.23, 1.2, 1.8 and 1.5 percent per 100,000 population from 2003 to 2009, respectively. The mean ages of patients in all cancers in both genders did not differ significantly through time (p value>0.05) but the distribution of ages of patients with bladder and prostate cancer changed significantly from 2003 to 2009 (p value<0.001). Conclusions: The results of present study suggest the general pattern and incidence of urological cancers in Iran are changing, the observed increase pointing to a need for urological cancer screening programs.